Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease - PubMed (original) (raw)
Case Reports
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
Daniel El Fassi et al. Gut. 2008 May.
No abstract available
Similar articles
- [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
Nielsen CH, El Fassi D, Hegedüs L. Nielsen CH, et al. Ugeskr Laeger. 2008 Jun 9;170(24):2131-4. Ugeskr Laeger. 2008. PMID: 18565295 Danish. - Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.
El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L. El Fassi D, et al. J Clin Endocrinol Metab. 2007 Oct;92(10):3762-3. doi: 10.1210/jc.2007-1238. J Clin Endocrinol Metab. 2007. PMID: 17933978 No abstract available. - Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab).
Bruzzese V, Pepe J. Bruzzese V, et al. Reumatismo. 2009 Oct-Dec;61(4):306-8. doi: 10.4081/reumatismo.2009.306. Reumatismo. 2009. PMID: 20143007 - B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L. Nielsen CH, et al. Expert Opin Biol Ther. 2007 Jul;7(7):1061-78. doi: 10.1517/14712598.7.7.1061. Expert Opin Biol Ther. 2007. PMID: 17665994 Review. - Rituximab in lupus and beyond: the state of the art.
Hughes G. Hughes G. Lupus. 2009 Jun;18(7):639-44. doi: 10.1177/0961203309105337. Lupus. 2009. PMID: 19433465 Review. No abstract available.
Cited by
- Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review.
Quesada-Simó A, Garrido-Marín A, Nos P, Gil-Perotín S. Quesada-Simó A, et al. Front Pharmacol. 2023 May 30;14:1186016. doi: 10.3389/fphar.2023.1186016. eCollection 2023. Front Pharmacol. 2023. PMID: 37324473 Free PMC article. Review. - The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration.
Hammadi SA, Almarzooqi S, Abdul-Kader HM, Saraswathiamma D, Souid AK. Hammadi SA, et al. Int J Physiol Pathophysiol Pharmacol. 2015 Dec 13;7(3):115-25. eCollection 2015. Int J Physiol Pathophysiol Pharmacol. 2015. PMID: 26823960 Free PMC article. - Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, Montacchini B, Covelli D, Guastella C, Pignataro L, Fugazzola L, Arosio M, Salvi M. Campi I, et al. Front Endocrinol (Lausanne). 2022 Jan 25;12:790246. doi: 10.3389/fendo.2021.790246. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35145479 Free PMC article. - Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.
Wilhelm AJ, Major AS. Wilhelm AJ, et al. Int J Clin Rheumtol. 2012 Oct 1;7(5):527-539. doi: 10.2217/ijr.12.46. Int J Clin Rheumtol. 2012. PMID: 24672580 Free PMC article. - Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.
Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, Kümpfel T, von Bubnoff N, Hohlfeld R, Berthele A, Hemmer B, Weber MS. Lehmann-Horn K, et al. J Neuroinflammation. 2011 Oct 26;8:146. doi: 10.1186/1742-2094-8-146. J Neuroinflammation. 2011. PMID: 22027448 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical